

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 March 2022 (17.03.2022)



(10) International Publication Number
WO 2022/053654 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/02 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2021/075016

(22) International Filing Date:

10 September 2021 (10.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/076,797 10 September 2020 (10.09.2020) US

(71) Applicant: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK).

(72) Inventors: **ELLIOT, Brian**; c/o Genmab US, Inc., 777 Scudders Mill Road, Plainsboro, New Jersey 08536 (US). **AHMADI, Tahamtan**; c/o Genmab US, Inc., 777 Scudders Mill Road, Plainsboro, New Jersey 08536 (US). **CHIU, Christopher**; c/o Genmab US, Inc., 777 Scudders Mill Road, Plainsboro, New Jersey 08536 (US). **BREIJ, Esther, C, W.**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **HIEMSTRA, Ida**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **JURE-KUNKEL, Maria, N.**; c/o Genmab Inc., 777 Scudders Mill Road, Plainsboro, New Jersey 08536 (US).

(74) Agent: **GENMAB A/S**; Kalvebod Brygge 43 IPR, 1560 Copenhagen V (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA




FIG. 2

(57) Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).



WO 2022/053654 A1